Fusen Pharmaceutical Sets 2026 AGM to Renew Board, Auditor and Share Issuance Mandate

An announcement from Fusen Pharmaceutical Co., Ltd. ( (HK:1652) ) is now available.

Fusen Pharmaceutical Company Limited has called its annual general meeting for 29 May 2026 in Hong Kong, where shareholders will review and adopt the audited consolidated financial statements and directors’ and auditors’ reports for the year ended 31 December 2025. Investors will also vote on the re-election of two executive directors and two independent non-executive directors, the re-appointment of CCTH CPA Limited as external auditors, and a mandate allowing the board to issue up to 20% of the company’s share capital, which could provide financial flexibility for future funding and capital management.

The proposed general mandate to allot and issue new shares, including the ability to sell or transfer treasury shares, underpins the company’s capacity to tap equity markets without convening separate shareholder meetings for each issuance. Approval of these resolutions would reaffirm the current governance structure and external audit relationship, while equipping the board with tools to respond more swiftly to capital needs or strategic opportunities, factors that current shareholders will weigh against potential dilution risks at the AGM.

More about Fusen Pharmaceutical Co., Ltd.

Fusen Pharmaceutical Company Limited is a Hong Kong–listed pharmaceutical firm incorporated in the Cayman Islands and traded on the Main Board of the Stock Exchange of Hong Kong. The company operates in the healthcare and pharmaceutical sector, focusing on the development, manufacture and sale of pharmaceutical products to serve patients and medical institutions in its core markets.

Average Trading Volume: 617,964

Technical Sentiment Signal: Buy

Current Market Cap: HK$867.6M

For detailed information about 1652 stock, go to TipRanks’ Stock Analysis page.